aTyr Pharma, Inc. filings document a clinical-stage biotechnology issuer focused on tRNA synthetase-derived medicines and the efzofitimod program for interstitial lung disease. Form 8-K reports furnish quarterly and annual results, corporate updates, and clinical-study disclosures, including EFZO-FIT results in pulmonary sarcoidosis.
Proxy materials describe board elections, stockholder meeting proposals, executive compensation, equity awards, and governance practices. The filing record also reflects capital-structure and stock-based compensation disclosures relevant to a development-stage biotechnology company funding research, clinical trials, and manufacturing activities for its lead program.
aTyr Pharma filed a charter amendment to effect a 1-for-40 reverse stock split, effective at 5:00 p.m. Eastern Time on October 28, 2026. The company stated that outstanding common shares will be reduced from approximately 100.5 million to approximately 2.5 million; authorized common shares will remain 340 million, and par value per share will not change.
The split will apply to all common shares outstanding immediately before effectiveness. Outstanding options, restricted stock units and warrants, along with equity-plan share reserves, will be adjusted proportionately; exercise prices for options and warrants will increase proportionately. Stockholders' percentage ownership will not change except where the split leaves a holder with only a fractional share, which will be rounded up to a whole share.
aTyr Pharma stockholders approved amendments authorizing the board, at its option, to effect a reverse stock split at a ratio between 1-for-10 and 1-for-50, inclusive, with the ratio set by the board in its sole discretion.
As of the September 4, 2026 record date, 98,087,425 common shares were outstanding and entitled to vote. At the October 16, 2026 special meeting, 57,915,370 shares were represented, approximately 59.04% of the record-date shares. The proposal received 52,451,734 votes for, 5,234,645 against and 228,991 abstentions.
aTyr Pharma Inc.'s ownership report states that Federated Hermes, Inc., the Voting Shares Irrevocable Trust, Thomas R. Donahue, Ann C. Donahue and J. Christopher Donahue reported beneficial ownership of 4,965,414 common shares, or 5.06%, as of September 30, 2026. Federated Hermes and the trust each listed sole voting and dispositive power over that amount; Thomas R. Donahue, Ann C. Donahue and J. Christopher Donahue listed shared voting and dispositive power. Thomas, Ann and J. Christopher are identified as trustees of the trust, and J. Christopher is also identified as Federated Hermes' president. The reporting persons expressly disclaim beneficial ownership of securities held by the Managed Funds.
aTyr Pharma Chief Financial Officer Brandon Yaras received an employee stock option award covering 410,000 shares of common stock on October 1, 2026. The option has an exercise price of $0.30 per share and expires October 1, 2036. It vests in 48 equal monthly installments beginning November 1, 2026, and will be fully exercisable on November 1, 2030. The option is subject to accelerated vesting upon termination without cause upon a change of control of the issuer.
aTYR Pharma CFO Brandon Yaras reports four direct employee stock option positions and 88,000 restricted stock units (RSUs); the remarks state that no securities are beneficially owned. The options relate to 70,000 shares at a $3.4800 exercise price, expiring May 10, 2032; 28,450 shares at $2.1950, expiring February 16, 2033; 55,000 shares at $1.5000, expiring January 5, 2034; and 84,142 shares at $3.7400, expiring January 8, 2035. Each RSU represents a contingent right to receive one common share.
aTyr Pharma (ATYR) announced alignment with the FDA on the protocol for a planned global Phase 3 study of efzofitimod in moderate to severe pulmonary sarcoidosis. The planned 54-week, randomized, double-blind, placebo-controlled study is intended to enroll up to approximately 372 patients with symptomatic pulmonary sarcoidosis and restrictive lung disease. Its design assigns patients to 5.0 mg/kg efzofitimod or placebo, given intravenously every three weeks for 17 doses, with background treatment remaining stable.
The primary endpoint is change from baseline in forced vital capacity at week 48; the key secondary endpoint is change from baseline in KSQ-Lung score at week 48. aTyr expects to focus on U.S. and European regulatory submissions as it initiates study-related activities in the fourth quarter of 2026. The company stated that future development will require additional capital through equity or debt offerings, grant funding, collaborations, strategic partnerships and/or licensing arrangements.
aTyr Pharma, Inc. (ATYR) is asking stockholders at a special meeting on October 16, 2026 to approve amendments to its certificate of incorporation that would authorize the Board to implement a reverse stock split of the common stock at a ratio between 1‑for‑10 and 1‑for‑50, at the Board’s discretion within one year of approval. The Board states the main goal is to help regain compliance with Nasdaq’s $1.00 minimum bid price requirement after receiving a deficiency notice and an extension to November 30, 2026, and to increase marketability and flexibility by effectively expanding available authorized but unissued shares. The Board may choose any ratio in the approved range, or decide not to implement a reverse split at all. Each holder’s ownership percentage would remain essentially unchanged, with fractional shares rounded up to the nearest whole share.
aTyr Pharma, Inc. (ATYR) is asking stockholders at an October 16, 2026 special meeting to approve amendments to its certificate of incorporation that would authorize the Board, in its sole discretion, to implement a reverse stock split of the common stock at any ratio between 1‑for‑10 and 1‑for‑50 within one year of approval.
The main stated goal is to help regain and maintain compliance with Nasdaq’s $1.00 minimum bid price requirement after the company received deficiency notices and an extended compliance deadline to November 30, 2026, and to potentially improve marketability and liquidity of the shares. A reverse split would not change each holder’s percentage ownership, aside from rounding up fractional shares, but would reduce shares outstanding while leaving the 340,000,000 authorized common shares unchanged, effectively increasing the pool of authorized but unissued shares, which could later be used for financing or other corporate purposes.
The proxy describes risks such as the possibility that the post‑split price may not stay above $1.00, potential reduced liquidity and more odd-lot holdings, and that the enlarged pool of authorized but unissued shares could have anti‑takeover implications. As of August 27, 2026, there were 98,087,425 shares outstanding; Federated Hermes, Inc. beneficially owned 8.68%, while all directors and executive officers as a group held 5.03%.
aTyr Pharma is a clinical-stage biotech focused on tRNA synthetase biology for fibrosis and inflammation. For the quarter ended June 30, 2026, it reported a consolidated net loss of $10.3 million (basic and diluted net loss per share of $0.11) and total operating expenses of $10.9 million, with research and development at $6.7 million and general and administrative at $4.1 million.
Cash, cash equivalents, restricted cash and available-for-sale investments totaled $58.9 million, and the company believes this will fund material cash requirements for at least one year. Net cash used in operating activities was $21.9 million for the first half of 2026. aTyr maintains an at-the-market equity program but did not use it in the period.
Lead candidate efzofitimod missed the primary endpoint in the prior EFZO-FIT Phase 3 pulmonary sarcoidosis trial but showed nominal improvements in several clinical measures. After FDA feedback, aTyr plans a new global Phase 3 study using forced vital capacity as the primary endpoint. The company is also running a Phase 2 SSc-ILD study (EFZO-CONNECT) and advancing ATYR0101 into IND-enabling work. A restructuring approved in August 2026 will reduce headcount by about 60% to 20 employees, with estimated $4.2 million in severance-related charges and expected annualized operating expense reductions of about $13 million. Rights to develop and commercialize efzofitimod in Japan reverted to aTyr following termination of its Kyorin collaboration, and the company disclosed ongoing putative securities class actions related to efzofitimod.
aTyr Pharma reported second quarter 2026 results and a major restructuring to prioritize its efzofitimod program for interstitial lung disease. Operating expenses were $10.9 million, including research and development of $6.7 million and general and administrative of $4.1 million, leading to a net loss attributable to aTyr of $10.3 million, or $0.11 per share, compared with $19.5 million, or $0.22 per share, a year earlier. Cash, cash equivalents, restricted cash and investments were $58.9 million as of June 30, 2026.
The company plans a workforce reduction of approximately 60% and other cost-saving measures it expects will reduce annualized operating expenses by about $13 million beginning in the fourth quarter of 2026 and support a cash runway into late 2028 while focusing resources on efzofitimod. Chief Financial Officer Jill Broadfoot and General Counsel Nancy Denyes will step down on September 30, 2026 and transition to consulting roles; Vice President of Finance Brandon Yaras will become CFO on October 1, 2026.
aTyr is awaiting U.S. Food and Drug Administration feedback by the end of August 2026 on a protocol for a planned global Phase 3 study of efzofitimod in pulmonary sarcoidosis and has completed enrollment in the Phase 2 EFZO-CONNECT study in SSc-ILD, with topline data expected in the first quarter of 2027.